SOCS proteins in immunity, inflammatory diseases, and immune-related cancer
Cytokine signaling represents one of the cornerstones of the immune system, mediating the
complex responses required to facilitate appropriate immune cell development and function …
complex responses required to facilitate appropriate immune cell development and function …
Hematologic cancers in individuals infected by HIV
A Carbone, E Vaccher… - Blood, The Journal of the …, 2022 - ashpublications.org
HIV infection increases cancer risk and is linked to cancers associated to infectious agents
classified as carcinogenic to humans by the International Agency for Research on Cancer …
classified as carcinogenic to humans by the International Agency for Research on Cancer …
Plasmablastic lymphoma: An update
Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma
frequently associated with immunosuppression, particularly human immunodeficiency virus …
frequently associated with immunosuppression, particularly human immunodeficiency virus …
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma
JE Ramis-Zaldivar, B Gonzalez-Farre… - …, 2021 - pmc.ncbi.nlm.nih.gov
Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with an
immunoblastic/large-cell morphology and terminal B-cell differentiation. The differential …
immunoblastic/large-cell morphology and terminal B-cell differentiation. The differential …
Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
A Künstner, HM Witte, J Riedl, V Bernard… - …, 2021 - pmc.ncbi.nlm.nih.gov
High-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or
BCL6 rearrangements (HGBL-DH/TH) poses a cytogenetically-defined provisional entity …
BCL6 rearrangements (HGBL-DH/TH) poses a cytogenetically-defined provisional entity …
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
F Frontzek, AM Staiger, M Zapukhlyak, W Xu… - Nature …, 2021 - nature.com
Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype
frequently associated with immunosuppression. Clinically, patients with PBL are …
frequently associated with immunosuppression. Clinically, patients with PBL are …
[HTML][HTML] Genome instability in multiple myeloma: facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated
with immunodeficiency, characterized by uncertain treatment approaches and an …
with immunodeficiency, characterized by uncertain treatment approaches and an …
[PDF][PDF] Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management
A Ramirez-Gamero, H Martínez-Cordero… - Am J …, 2024 - researchgate.net
Abstract Disease Overview: Plasmablastic lymphoma (PBL) is a rare CD20-negative
aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL …
aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL …
Clinical and therapeutic implications of Epstein–Barr virus in HIV-related lymphomas
M Verdu-Bou, G Tapia, A Hernandez-Rodriguez… - Cancers, 2021 - mdpi.com
Simple Summary Epstein–Barr virus (EBV) is involved in lymphomagenesis, especially
lymphomas affecting populations with immunodeficiencies, such as people living with HIV …
lymphomas affecting populations with immunodeficiencies, such as people living with HIV …